A single dose of the lysergide orally disintegrating tablet achieved statistically significant MADRS improvement at six weeks compared …
A single dose of the lysergide orally disintegrating tablet achieved statistically significant MADRS improvement at six weeks compared …
Amtagvi becomes the first tumour-infiltrating lymphocyte therapy approved in Australia for advanced melanoma, entering a market with the …
BlueRock Therapeutics reports that a single transplant of dopaminergic progenitors derived from pluripotent stem cells produced durable reductions …
The RMAT-designated GABAergic interneuron cell therapy for drug-resistant mesial temporal lobe epilepsy demonstrated sustained seizure control in updated …
Arvinas’ vepdegestrant (VEPPANU) demonstrated a 43% reduction in risk of disease progression versus fulvestrant in the pivotal VERITAC-2 …
Four-year open-label extension data for zorevunersen reinforce the antisense oligonucleotide’s disease-modifying potential in SCN1A-linked epilepsy, as the pivotal …
The allogeneic GABAergic interneuron cell therapy reported durable seizure suppression beyond 13 months in drug-resistant mesial temporal lobe …
The TGA has granted conditional approval to Iovance Biotherapeutics’ lifileucel, an autologous tumour-infiltrating lymphocyte therapy, bringing a new …
Arvinas’s vepdegestrant (VEPPANU) marks a regulatory milestone as the first proteolysis-targeting chimera to win FDA approval, offering a …
Led by Founders Fund and Thrive Capital, the round reflects sustained institutional conviction in cellular rejuvenation biology as …
Already a subscriber? Log in